Ipsen's First Focus Is Endocrinology As Firm Moves Toward Specialty Care
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
As Ipsen shifts away from an emphasis on primary care and toward specialty care therapies – a move straight out of Big Pharma’s playbook – endocrinology will become a pillar of its specialty care pipeline.
You may also be interested in...
Older Primary Care Drugs Matter – For Cash, And For Emerging Market Access
Europe's mid-sized pharma may be going specialist like much of the rest of the industry, including some of the biggest companies
Older Primary Care Drugs Matter – For Cash, And For Emerging Market Access
Europe's mid-sized pharma may be going specialist like much of the rest of the industry, including some of the biggest companies
Ipsen Confident in U.S. Neurology Push Despite Dysport Delay
Neither FDA’s REMS request nor the prospect of competing with Allergan’s Botox appears to be spoiling Ipsen’s plans to stake a U.S. neurology stronghold.